Get started
Author

Laura Scortichini

Observed names: L. Scortichini, Scortichini, Laura
ORCID: 0000-0002-3196-3331
Observed ORCID: 0000-0002-3196-3331
OpenAlex ID: A5008990964
Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management
2020 · Rossana Berardi, Francesca Morgese, et al. · Cancer Management and Research · 160
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management
2020 · Giulia Mentrasti, Laura Scortichini, et al. · Therapeutics and Clinical Risk Management · 48
PDF
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
2021 · Elena Maccaroni, Riccardo Giampieri, et al. · World Journal of Clinical Oncology · 26
Systemic treatment for lung carcinoids: from bench to bedside
2019 · Mariangela Torniai, Laura Scortichini, et al. · Clinical and Translational Medicine · 24
PDF
The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience
2021 · Mirco Pistelli, Valentina Natalucci, et al. · Cancers · 18
PDF
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
2021 · Mirco Pistelli, Filippo Merloni, et al. · Journal of Oncology · 13
PDF
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
2019 · Filippo Merloni, Nicoletta Ranallo, et al. · Cancer Drug Resistance · 8
PDF
Potential immune‑related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma
2022 · Francesca Morgese, Valeria Cognigni, et al. · Molecular and Clinical Oncology · 5
PDF
Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
2024 · Matteo Giulietti, Francesco Piva, et al. · Cells · 3
PDF
Management of lung cancer patients during COVID-19 pandemic: dos, don’ts and don’t knows
2022 · Mariangela Torniai, Veronica Agostinelli, et al. · Exploration of Targeted Anti-tumor Therapy · 1
PDF
Abstract PD11-03: Assessing the impact of 12 months lifestyle interventions on breast cancer secondary prevention: A modeling approach
2021 · Mirco Pistelli, Valentina Natalucci, et al. · Cancer Research · 1
Sacituzumab govitecan nel tumore della mammella ER+/HER2-: un’opzione necessaria nelle pazienti pluritrattate
2026 · Laura Scortichini, Nicola Battelli · Recenti Progressi in Medicina
PDF
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study
2025 · Marina Elena Cazzaniga, Paolo Pronzato, et al. · Cancers
PDF
219P New prognostic factors in advanced HR+ HER2- breast cancer treated with CDK4/6 inhibitors
2024 · S. Crocetti, M. Pistelli, et al. · ESMO Open
PDF
Caregiving during the COVID-19 pandemic: the new challenge in oncology assistance?
2024 · Crocetti, Sonia, Ballatore, Zelmira, et al. · Acta bio-medica dell'Ateneo parmense/Acta biomedica
PDF
Works count: 16
Citation count: 307
H-index: 7
I10-index: 6
Year
Topic
Type